Mirae Asset Global Etfs Holdings Ltd. Uro Gen Pharma Ltd. Transaction History
Mirae Asset Global Etfs Holdings Ltd.
- $43.9 Billion
- Q4 2024
A detailed history of Mirae Asset Global Etfs Holdings Ltd. transactions in Uro Gen Pharma Ltd. stock. As of the latest transaction made, Mirae Asset Global Etfs Holdings Ltd. holds 21,667 shares of URGN stock, worth $260,437. This represents 0.0% of its overall portfolio holdings.
Number of Shares
21,667
Previous 20,698
4.68%
Holding current value
$260,437
Previous $262,000
12.21%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding URGN
# of Institutions
137Shares Held
36.2MCall Options Held
57.7KPut Options Held
9.8K-
Rtw Investments, LP New York, NY3.83MShares$46.1 Million0.67% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA2.93MShares$35.2 Million0.06% of portfolio
-
Menora Mivtachim Holdings Ltd.2.3MShares$27.7 Million0.15% of portfolio
-
Black Rock Inc. New York, NY2.19MShares$26.4 Million0.0% of portfolio
-
Toronto Dominion Bank Toronto, Ontario, A61.75MShares$21 Million0.03% of portfolio
About UroGen Pharma Ltd.
- Ticker URGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 22,740,500
- Market Cap $273M
- Description
- UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead...